Search Results
Your search for ,ARE matches 21433 pages
Showing 2751 - 2800I’m BRCA-Positive and Survived Both Breast and Pancreatic Cancers
Cancer has stalked my family for generations. My mother, brother, and maternal uncle were diagnosed with melanoma. Fortunately, all survived. When my sister was diagnosed with early-stage invasive ductal carcinoma in 2010, she underwent genetic testing, which showed she was positive for the BRCA2...
ASCO Member Testifies Before Congress, Urging Significant Increase in Federal Cancer Research Funding
Brian Persing, MD, a medical oncologist and hematologist in Mobile, Alabama, and a member of ASCO, the world’s leading professional organization representing nearly 45,000 oncology professionals, testified before the House Appropriations Subcommittee on Labor Health and Human Services and...
Emerging Success With Novel Targeted Therapies in Endocrine-Resistant Metastatic Breast Cancer
In hormone receptor–positive breast cancer, the ability to successfully target key mediators of endocrine resistance is changing the outlook of metastatic disease in this subtype, according to Aditya Bardia, MD, MPH, FASCO, Director of Breast Cancer Research and Associate Professor at Harvard...
Expert Point of View: Callisia N. Clarke, MD, MS, FACS, FSSO
Moderator of the press conference at the 2023 Society of Surgical Oncology (SSO) International Conference on Surgical Cancer Care, Callisia N. Clarke, MD, MS, FACS, FSSO, Assistant Professor of Surgery, Medical College of Wisconsin, shared insights on the transition of circulating tumor DNA...
Using Circulating Tumor DNA to Predict Early Recurrence of Soft-Tissue Sarcomas
Circulating tumor DNA (ctDNA) may transform disease monitoring and guide treatment for soft-tissue sarcomas, according to data presented at the 2023 Society of Surgical Oncology (SSO) International Conference on Surgical Cancer Care.1 Findings of a retrospective review showed that 85% of patients...
Social Drivers of Health: Grabbing the Steering Wheel
Study after study has demonstrated race-based differences in survival and other clinical outcomes for patients with cancer. But as health professionals, we are learning that these differences are less about a patient’s skin color and more about the legacy of racial inequality.1 This knowledge...
Expert Point of View: Yelena Y. Janjigian, MD
The GLOW study’s invited discussant, Yelena Y. Janjigian, MD, Chief of the Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center, New York, said the GLOW findings are “practice-changing,” validating that high claudin-18.2 (CLDN18.2) expression as an important biomarker in...
GLOW Trial: Zolbetuximab Plus Chemotherapy Sets New Treatment Standard in Gastric Cancer Subset
In the first-line setting, the monoclonal antibody zolbetuximab in combination with chemotherapy extended overall survival in patients with claudin-18.2 (CLDN18.2)-positive, HER2-negative, locally advanced or metastatic gastric adenocarcinoma. This regimen is now positioned as a new standard of...
Expert Point of View: Rebecca Arend, MD, MSH and Ilaria Colombo, MD
“Endometrial cancer is the most frequently diagnosed gynecologic malignancy in the United States, and it is the only one where the mortality has actually risen over the past 40 years,” noted Rebecca Arend, MD, MSH, Associate Professor at the University of Alabama and Associate Scientist in the...
Checkpoint Inhibitors Poised to Change Standard of Care in Advanced Endometrial Cancer
The addition of a checkpoint inhibitor to standard chemotherapy as first-line treatment of advanced endometrial cancer reduced the risk of disease progression or death by 70% in patients with mismatch repair–deficient (dMMR) tumors in two recent phase III studies. The results of the two...
Vitamin D Deficiencies May Lead to Health Disparities in Black Patients With Prostate Cancer
Investigators have found that vitamin D deficiencies may contribute to more aggressive prostate cancer in Black patients at a younger age compared with White patients, according to a new study published by Siddappa et al in Cancer Research Communications. The new findings could pave the way for...
Black Patients With Cancer May Be More Likely to Experience Cardiotoxicity Following Chemotherapy
Chemotherapy may be associated with a 71% increased risk of treatment-related cardiotoxicity—including heart failure and cerebrovascular disease—among Black patients or patients of African ancestry compared with White patients, according to new findings presented by Gebeyehu et al at the American...
Extreme Poverty May Be a Key Driver for Relapse in Pediatric Patients With ALL
Pediatric patients with acute lymphoblastic leukemia (ALL) living in extreme poverty and undergoing maintenance therapy may have almost a twofold greater risk of relapse compared with pediatric patients who weren’t living in extreme poverty, according to a new study published by Wadhwa et al in...
Neoadjuvant Trabectedin and Radiotherapy in Myxoid Liposarcoma
In the phase II TRASTS study reported in JAMA Oncology, Sanfilippo et al found that neoadjuvant trabectedin and radiotherapy did not meet the target objective response rate per Response Evaluation Criteria in Solid Tumors (RECIST) in patients with myxoid liposarcoma but did exhibit activity...
Locally Advanced High-Risk Prostate Cancer
This is Part 3 of Novel Hormonal Therapies for Prostate Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Alicia K. Morgans, Neeraj Agarwal, and David VanderWeele discuss the management of locally advanced high-risk...
Early Trial Results Show Potential Benefits of FGFR Inhibitors and PARP/ATR Inhibitor Combinations in Multiple Tumor Types
In three new clinical trials, researchers have found that the novel fibroblast growth factor receptor (FGFR) inhibitor pemigatinib and new poly (ADP ribose) polymerase (PARP)/ataxia telangiectasia and Rad3-related (ATR) inhibitor combinations may be effective at treating patients with multiple...
Patients With Brain Metastases From Renal Cell Carcinoma May Have Distinct Immunosuppressive Tumor Microenvironment
Researchers have created the largest single-cell atlas of renal cell carcinoma brain metastases, with matched primary and extracranial metastases, which has potentially enabled them to discover key biological mechanisms contributing to an immunosuppressive tumor microenvironment in the brain...
COVID-19 Pandemic May Have Disrupted Cancer Reporting in 2020 and Beyond
Investigators have uncovered factors contributing to the COVID-19 pandemic’s destabilization of the usual patterns of cancer care, described specific ways that National Cancer Database data models were impacted by the pandemic, and offered guidance to cancer centers across the United States on how...
Highlights From the AACR Annual Meeting 2023
On this episode, we are sharing news presented during the American Association for Cancer Research (AACR) Annual Meeting, which was held earlier this month in Orlando. We feature three researchers discussing their findings in non–small cell lung cancer, early-stage breast cancer, and solid tumors...
Validation of a Prognostic Model for Overall Survival in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer
In a study reported in the Journal of Clinical Oncology, Susan Halabi, PhD, and colleagues validated an overall survival prognostic model for docetaxel-naive patients with metastatic castration-resistant prostate cancer. As noted by the investigators, “We have previously developed and externally...
Study Identifies Mutations That May Be Associated With Poor Outcomes in Patients With NSCLC Treated With KRAS G12C Inhibitors
Researchers have discovered that co-occurring mutations in three tumor-suppressor genes—KEAP1, SMARCA4, and CDKN2A—may be linked with poor clinical outcomes in patients with KRAS G12C–mutant non–small cell lung cancer (NSCLC) who were treated with the KRAS G12C inhibitors adagrasib or sotorasib,...
Novel CAR T-Cell Therapy Under Study in Metastatic Clear Cell Renal Cell Carcinoma
Treatment with the allogeneic chimeric antigen receptor (CAR) T-cell therapy ALLO-316 resulted in encouraging response rates and disease control rates for patients with metastatic clear cell renal cell carcinoma who did not respond to prior therapy, according to new findings presented by Srour et...
VT3989 May Be Safe, Effective in Patients With Advanced Mesothelioma and NF2-Mutant Solid Tumors
The yes-associated protein (YAP)/transcriptional enhancer activator domain (TEAD) inhibitor VT3989 may have been well tolerated with durable antitumor responses in patients with advanced malignant mesothelioma as well as other NF2-mutated solid tumors, according to new findings presented by Yap et...
Karriem S. Watson, DHSc, on Early Engagement in Clinical Trials for Underrepresented Communities
Karriem S. Watson, DHSc, MPH, of the National Institutes of Health All of Us Research Program, discusses the importance of engaging in clinical trials for those who are underrepresented in biomedical research. Community engagement is a proven and effective tool, Dr. Watson says, to enhance...
Whole-Exome Sequencing May Help Identify Individuals With Cancer Predisposition Syndromes Missed by Current Screening Guidelines
Researchers revealed that 39.2% of patients who consented to whole-exome sequencing and were identified as carriers of predisposition genes for hereditary breast and ovarian cancer or Lynch syndrome did not qualify for genetic screening under current guidelines, according to new findings presented...
Investigational Deep Learning Model May Help Stratify Risk of Distant Recurrence in Patients With Endometrial Cancer
An investigational deep learning model requiring one histopathologic slide may be effective at predicting the risk of distant recurrence in patients with endometrial cancer, according to novel findings presented by Fremond et al at the American Association for Cancer Research (AACR) Annual Meeting...
Olaparib Plus Ceralasertib May Benefit Pediatric Patients With Cancer Who Have DNA Replication and/or Damage Repair–Deficient Tumors
Researchers have found that a combination of the PARP inhibitor olaparib and the investigational ATR inhibitor ceralasertib showed clinical benefit in pediatric patients with solid tumors exhibiting DNA replication and/or damage repair deficiencies, according to new findings presented by Gatz et al ...
Immune Checkpoint Inhibition and Long-Term Survival in Patients With Metastatic Urothelial Cancer
In an analysis reported in JAMA Network Open, Zhu et al found that immune checkpoint inhibitor treatment did not appear to be associated with long-term survival in patients with metastatic urothelial cancer. Study Details The analysis included data from six trials of pembrolizumab, avelumab, and...
Bispecific Antibody REGN5459 Shows Activity in Patients With Relapsed or Refractory Multiple Myeloma
Although the 5-year relative survival rate for multiple myeloma is improving—up from 34.6% in 1998 to 53.9% in 2016—due to the approval of more effective therapies, multiple myeloma remains incurable, and new treatment options are needed, especially in the relapsed/refractory setting. A small phase ...
Liquid Biopsy–Based Multicancer Early Detection Test May Find Early-Stage and Low DNA–Shedding Cancers
Although plasma cell-free DNA (cfDNA) tests represent a promising approach for cancer screening, different methodologies vary in performance and many liquid biopsy tests show decreased performance in detecting early-stage or low-shedding DNA tumors. However, the results from a retrospective...
Study Explores Genomic Basis of Racial Disparities Among Patients With Colorectal Cancer
Black individuals are disproportionately affected by colorectal cancer. They have the highest rates of the disease of any racial or ethnic group in the United States, and are about 20% more likely to develop colorectal cancer and about 40% more likely to die of the disease than most other groups. A ...
Study Finds Lung Cancer Incidence Rates Vary Significantly Among Florida’s Black and Hispanic Ethnic Subgroups
An analysis of lung cancer incidence rates showed wide variations among the racial and ethnic subgroups in Florida’s Black and Hispanic population, according to data presented by Cranford et al at the American Association for Cancer Research (AACR) Annual Meeting 2023 (Abstract 1902/8). Study...
Awareness of the Link Between HPV and Cervical Cancer Has Declined Between 2014 and 2020
Americans have become less aware that the human papillomavirus (HPV) causes cervical cancer in recent years, according to survey data presented by Adjei Boakye et al at the American Association for Cancer Research (AACR) Annual Meeting 2023 (Abstract 4210 /11). Survey respondents also showed low...
FDA Approves Omidubicel-onlv to Reduce Time to Neutrophil Recovery and Infection in Patients With Hematologic Malignancies
On April 17, the U.S. Food and Drug Administration (FDA) approved omidubicel-onlv (Omisirge) for use in adult and pediatric patients aged 12 years and older with hematologic malignancies who are planned for umbilical cord blood transplantation following myeloablative conditioning to reduce the time ...
IMbrave050: Recurrence-Free Survival With Adjuvant Atezolizumab Plus Bevacizumab for HCC
Adjuvant therapy with atezolizumab and bevacizumab improved recurrence-free survival in patients with hepatocellular carcinoma (HCC) following surgical resection or ablation, according to results from the phase III IMbrave050 clinical trial, which were presented by Chow et al at the American...
NIH Study Outlines Opportunities to Achieve Cancer Moonshot Goal of Reducing Cancer Mortality in the United States
Researchers from the National Institutes of Health (NIH) have outlined opportunities for achieving President Joe Biden and First Lady Jill Biden’s Cancer Moonshot national goal of reducing the cancer death rate by at least 50% over the next 25 years. A study published by Shiels et al in Cancer...
Single-Agent Pembrolizumab May Benefit Patients With Advanced Desmoplastic Melanoma
Monotherapy with pembrolizumab led to clinical responses in 89% of patients with unresectable metastatic desmoplastic melanoma, according to results from the phase II S1512 clinical trial presented by Kendra et al at the American Association for Cancer Research (AACR) Annual Meeting 2023 (Abstract...
Personalized mRNA-Based Cancer Vaccine Plus Pembrolizumab for High-Risk Melanoma
mRNA-4157/V940, a personalized mRNA-based cancer vaccine, in combination with the immune checkpoint inhibitor pembrolizumab improved recurrence-free survival compared with pembrolizumab alone in patients with high-risk melanoma, and clinical benefit was observed regardless of tumor mutational...
First-Line Pembrolizumab Plus Gemcitabine/Cisplatin May Improve Overall Survival in Advanced Biliary Tract Cancer
The addition of pembrolizumab to gemcitabine and cisplatin improved overall survival in patients with untreated metastatic or unresectable biliary tract cancer, according to results from the phase III KEYNOTE-966 clinical trial, which were presented by Robin Katie Kelley, MD, and colleagues at the...
Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Patients With Resectable NSCLC: AEGEAN Trial
Treatment-naive patients with resectable non–small cell lung cancer (NSCLC) who received neoadjuvant durvalumab plus chemotherapy and adjuvant durvalumab monotherapy had improved event-free survival and pathologic complete response compared with those who received neoadjuvant chemotherapy alone,...
Addressing Racial Disparities in Cancer Pain Management: A Potential Role for Music Therapy
Guest Editor’s Note: Despite its high prevalence, cancer pain remains undertreated. Racial disparities present further challenges to assessing and managing pain. Music therapy, a nonpharmacologic intervention, has been documented to be effective in controlling cancer pain. In this article, Kevin T. ...
MRD and KMT2A Fusion Partners in Predicting Outcomes of Childhood KMT2A-Rearranged Acute Myeloid Leukemia
In a retrospective study reported in the Journal of Clinical Oncology, van Weelderen et al, of the International Berlin-Frankfurt-Münster Study Group (I-BFM-SG), found that KMT2A fusion partners and measurable residual disease (MRD) at end of induction phase 2 were independent predictors of...
Update on Withdrawal of Ibrutinib Accelerated Approvals for MCL and MZL in the United States
AbbVie announced that it intends to voluntarily withdraw, in the United States, accelerated ibrutinib (Imbruvica) approvals for patients with mantle cell lymphoma (MCL) who have received at least one prior therapy as well as patients with marginal zone lymphoma (MZL) who require systemic therapy...
Pragmatica-Lung Trial Begins Enrolling Patients With NSCLC Who Did Not Respond to Previous Therapy
The National Cancer Institute (NCI) announced that it has helped launch the randomized phase III Pragmatica-Lung trial examining the efficacy of ramucirumab plus pembrolizumab in treating patients with advanced non–small cell lung cancer (NSCLC). The new study is one of the first NCI-supported...
Digital Breast Tomosynthesis May Improve Breast Cancer Screening Performance in Community Settings
Researchers have found that digital breast tomosynthesis may have improved breast cancer screening performance in community practices and could be effective at identifying more invasive cancers compared with digital mammography, according to a new study published by Lee et al in Radiology. The...
Statewide Survey May Provide Insight Into Cancer-Related Knowledge, Beliefs, and Behaviors of Hispanic Individuals in Indiana
A new survey of Hispanic adults residing in Indiana may present a snapshot of their cancer-related knowledge, beliefs, and behaviors and provide guidance for the future development of tailored cancer screening messaging and prevention strategies, according to a study published by Espinoza-Gutarra...
Cancer Susceptibility Germline Pathogenic Variants Among Older Patients
Hereditary cancer syndromes are caused by a pathogenic variant in cancer susceptibility genes, which overall account for approximately 10% of all cancers. Carriers of pathogenic variants are at an increased risk of developing cancer during their lifetime. Genomic cancer risk assessment makes it...
Novel Device May Be Safe, Effective Chemotherapy Delivery System for Patients With Muscle-Invasive Bladder Cancer Who Are Unfit for Standard Therapy
Researchers have found that the novel intravesical chemotherapy delivery system TAR-200 may be safe and effective for patients with advanced muscle-invasive bladder cancer who are medically unfit for standard treatment, according to a new study published by Tyson et al in The Journal of Urology....
Financial Toxicity of Cancer May Impact Partner’s Quality of Life
Researchers have discovered that the financial impact of an individual’s cancer diagnosis may also impact a partner’s health-related quality of life, according to a new study published by Ghazal et al in JAMA Network Open. “When you think of key developmental milestones young adults expect to...
Prior CTLA-4 Inhibition May Influence Response to PD-1 Inhibitors in Patients With Advanced Melanoma
Researchers have found that responses to PD-1 inhibitor treatment in patients with advanced melanoma may depend on whether they had received previous treatment with CTLA-4 inhibitors, according to a new study published by Campbell et al in Cancer Cell. “In our large set of data, features that have...
